Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino, Thomas Danne, Richard M. Bergenstal, Stephanie A. Amiel, Roy W. Beck, Torben Biester, Emanuele Bosi, Bruce A. Buckingham, William T. Cefalu, Kelly L. Close, Claudio Cobelli, Eyal Dassau, J. Hans DeVries, Kim C. Donaghue, Klemen Dovč, Francis J. Doyle, Satish K. Garg, George Grunberger, Simon R. Heller, Lutz Heinemann, Irl B. Hirsch, Roman Hovorka, Weiping Jia, Olga Kordonouri, Boris P. Kovatchev, Aaron J. Kowalski, Lori M. Laffel, Brian J. Levine, Alexander Yur'evich Mayorov, Chantal Mathieu, Helen R. Murphy, Revital Nimri, Kirsten Nørgaard, Christopher G. Parkin, Éric Renard, David Rodbard, Banshi Saboo, Desmond Schatz, KEATON C. STONER, Tatsuiko Urakami, STUART ALAN WEINZIMER, Moshe Phillip
Diabetes Care · 2019 · 4,292 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R. W., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovč, K., Doyle, F. J., Garg, S. K., Grunberger, G., Heller, S. R., … Phillip, M. (2019). Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care, 42(8), 1593–1603. https://doi.org/10.2337/dci19-0028
In text: (Battelino et al., 2019)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Related papers
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus1993
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin2002
- International Diabetes Federation 20172018
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015
- Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance2001
Metadata from OpenAlex (CC0). Citations are generated from the published record.